All In Biotech

Drug Trial Radar · NCT04187560

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

A Randomized, Double-blinded, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LB-102 Administered Orally to Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Dec 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Jan 22, 2020

Primary completion

Jul 1, 2020

Study completion Nov 9, 2020

Sponsor

Lead sponsor
LB Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Dec 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Single Ascending Dose (SAD; Part A) and Multiple Ascending Dose (MAD; Part B) Phase 1 Study of LB-102 N-Methyl amisulpride) in healthy volunteers. The primary objective is to evaluate the safety and the tolerability of a single oral dose (SAD) and multiple oral doses (MAD) of LB-102 as compared to placebo. The secondary objectives are to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of LB-102.

Conditions

  • Schizophrenia

Interventions

  • LB-102Drug

    (N-Methyl amisulpride)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who experience at least one treatment-emergent adverse event (TEAE)Time frame: Day 8 (Part A) or Day 15 (Part B)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medpace Clinical Pharmacology LLC

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.